

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- a) a polypeptide comprising an amino acid sequence of SEQ ID NO:1,
- b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1,
- c) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:1, and
- d) an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:1.

2. An isolated polypeptide of claim 1, having a sequence of SEQ ID NO:1.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

4. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

5. A cell transformed with a recombinant polynucleotide of claim 4.

6. A transgenic organism comprising a recombinant polynucleotide of claim 4.

7. A method for producing a polypeptide of claim 1, the method comprising:

- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
- b) recovering the polypeptide so expressed.

8. An isolated antibody which specifically binds to a polypeptide of claim 1.

9. An isolated polynucleotide comprising a sequence selected from the group consisting of:

- 5           a)       a polynucleotide comprising a polynucleotide sequence of SEQ ID NO:2,  
          b)       a naturally occurring polynucleotide comprising a polynucleotide sequence  
at least 90% identical to a polynucleotide sequence of SEQ ID NO:2,  
          c)       a polynucleotide having a sequence complementary to a polynucleotide of a),  
          d)       a polynucleotide having a sequence complementary to a polynucleotide of b)  
10       and  
          e)       an RNA equivalent of a)-d).

10. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 9.

11. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 9, the method comprising:

- a)       hybridizing the sample with a probe comprising at least 20 contiguous  
nucleotides comprising a sequence complementary to said target polynucleotide in the  
sample, and which probe specifically hybridizes to said target polynucleotide, under  
conditions whereby a hybridization complex is formed between said probe and said target  
polynucleotide or fragments thereof, and  
          b)       detecting the presence or absence of said hybridization complex, and,  
optionally, if present, the amount thereof.

12. A method of claim 11, wherein the probe comprises at least 60 contiguous nucleotides.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 9, the method comprising:

a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

5

14. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

10

15. A composition of claim 14, wherein the polypeptide has an amino acid sequence of SEQ ID NO:1.

16. A method for treating a disease or condition associated with decreased expression of functional LGFV, comprising administering to a patient in need of such treatment the composition of claim 14.

15

17. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting agonist activity in the sample.

20

18. A composition comprising an agonist compound identified by a method of claim 17 and a pharmaceutically acceptable excipient.

25

19. A method for treating a disease or condition associated with decreased expression of functional LGFV, comprising administering to a patient in need of such treatment a composition of claim 18.

20. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

30

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

- b) detecting antagonist activity in the sample.

21. A composition comprising an antagonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with overexpression of functional LGFV, comprising administering to a patient in need of such treatment a composition of claim 21.

23. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and  
b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

24. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,  
b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and  
c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

25. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide

sequence of SEQ ID NO:2, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

26. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 9 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 9 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

27. A diagnostic test for a condition or disease associated with the expression of LGFV in a biological sample comprising the steps of:

- a) combining the biological sample with an antibody of claim 8, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

28. The antibody of claim 8, wherein the antibody is:

- a) a chimeric antibody,

- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')<sub>2</sub> fragment, or
- e) a humanized antibody.

5

29. A composition comprising an antibody of claim 8 and an acceptable excipient.

30. A method of diagnosing a condition or disease associated with the expression of LGFV in a subject, comprising administering to said subject an effective amount of the composition of claim 29.

10

31. A composition of claim 29, wherein the antibody is labeled.

32. A method of diagnosing a condition or disease associated with the expression of LGFV in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

15

33. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 8 comprising:

20

a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

b) isolating antibodies from said animal; and

c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

25

34. An antibody produced by a method of claim 33.

35. A composition comprising the antibody of claim 34 and a suitable carrier.

30

36. A method of making a monoclonal antibody with the specificity of the antibody of claim 8 comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
- b) isolating antibody producing cells from the animal;
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
- d) culturing the hybridoma cells; and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

37. A monoclonal antibody produced by a method of claim 36.

38. A composition comprising the antibody of claim 37 and a suitable carrier.

39. The antibody of claim 8, wherein the antibody is produced by screening a Fab expression library.

40. The antibody of claim 8, wherein the antibody is produced by screening a recombinant immunoglobulin library.

41. A method for detecting a polypeptide having an amino acid sequence of SEQ ID NO:1 in a sample, comprising the steps of:

- a) incubating the antibody of claim 8 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence of SEQ ID NO:1 in the sample.

42. A method of purifying a polypeptide having an amino acid sequence of SEQ ID

NO:1 from a sample, the method comprising:

- a) incubating the antibody of claim 8 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
- b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence of SEQ ID NO:1.

43. A microarray wherein at least one element of the microarray is a polynucleotide of claim 10.

44. A method for generating a transcript image of a sample which contains polynucleotides, the method comprising the steps of:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 43 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

45. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, said target polynucleotide having a sequence of claim 9.

46. An array of claim 45, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

47. An array of claim 45, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.



48. An array of claim 45, which is a microarray.

49. An array of claim 45, further comprising said target polynucleotide hybridized to said first oligonucleotide or polynucleotide.

50. An array of claim 45, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

51. An array of claim 45, wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.